AbbVie Inc. (NYSE:ABBV)


Analyse des ratios de rentabilité
Données trimestrielles

Niveau de difficulté faible


Ratios de rentabilité (résumé)

AbbVie Inc., ratios de rentabilité (données trimestrielles)

Microsoft Excel LibreOffice Calc
31 mars 2020 31 déc. 2019 30 sept. 2019 30 juin 2019 31 mars 2019 31 déc. 2018 30 sept. 2018 30 juin 2018 31 mars 2018 31 déc. 2017 30 sept. 2017 30 juin 2017 31 mars 2017 31 déc. 2016 30 sept. 2016 30 juin 2016 31 mars 2016 31 déc. 2015 30 sept. 2015 30 juin 2015 31 mars 2015
Ratios de vente
Ratio de marge bénéficiaire brute 77.43% 77.64% 77.32% 77.41% 77.07% 76.44% 75.22% 74.93% 75.18% 75.05% 76.85% 76.78% 76.81% 77.25% 77.21% 78.12% 79.28% 80.31%
Ratio de marge bénéficiaire d’exploitation 39.86% 39.03% 20.04% 21.85% 19.88% 19.49% 32.99% 32.84% 34.03% 33.99% 37.24% 36.74% 36.33% 36.60% 36.21% 35.00% 34.18% 32.97%
Ratio de marge bénéficiaire nette 24.77% 23.69% 9.90% 12.62% 16.42% 17.36% 23.50% 20.84% 21.55% 18.82% 24.38% 24.77% 24.07% 23.22% 24.08% 23.11% 23.03% 22.50%
Ratios d’investissement
Rendement des capitaux propres (ROE) 179.59% 104.16% 99.42% 110.08% 126.25% 128.41% 93.97% 101.42% 117.94% 130.39%
Ratio de rendement des actifs (ROA) 9.25% 8.84% 5.48% 7.21% 9.44% 9.58% 11.43% 10.46% 9.20% 7.50% 9.66% 9.87% 9.61% 9.01% 9.12% 8.51% 10.19% 9.70%

La source: AbbVie Inc. (NYSE:ABBV) | Analysis of profitability ratios (Q) (www.stock-analysis-on.net)

Ratio de rentabilité La description L’entreprise
Ratio de marge bénéficiaire brute Le ratio de marge bénéficiaire brute indique le pourcentage des revenus disponibles pour couvrir les dépenses d’exploitation et autres. Le ratio de marge bénéficiaire brute d’AbbVie Inc. s’est amélioré du troisième trimestre 2019 au quatrième trimestre 2019, puis s’est légèrement détérioré du quatrième trimestre 2019 au premier trimestre 2020, n’atteignant pas le niveau du troisième trimestre 2019.
Ratio de marge bénéficiaire d’exploitation Un ratio de rentabilité calculé comme le résultat d’exploitation divisé par le chiffre d’affaires. Le ratio de marge bénéficiaire d’exploitation d’AbbVie Inc. s’est amélioré du troisième trimestre 2019 au quatrième trimestre 2019 et du quatrième trimestre 2019 au premier trimestre 2020.
Ratio de marge bénéficiaire nette Un indicateur de rentabilité, calculé comme le revenu net divisé par les revenus. Le ratio de marge bénéficiaire nette d’AbbVie Inc. s’est amélioré du troisième trimestre 2019 au quatrième trimestre 2019 et du quatrième trimestre 2019 au premier trimestre 2020.

Ratio de rentabilité La description L’entreprise
ROE Un ratio de rentabilité calculé en résultat net divisé par les capitaux propres.
ROA Un ratio de rentabilité calculé comme le bénéfice net divisé par le total de l’actif. Le ROA d’AbbVie Inc. s’est amélioré du troisième trimestre 2019 au quatrième trimestre 2019 et du quatrième trimestre 2019 au premier trimestre 2020.

Ratio de marge bénéficiaire brute

AbbVie Inc., ratio de marge bénéficiaire brute, calcul (données trimestrielles)

Microsoft Excel LibreOffice Calc
31 mars 2020 31 déc. 2019 30 sept. 2019 30 juin 2019 31 mars 2019 31 déc. 2018 30 sept. 2018 30 juin 2018 31 mars 2018 31 déc. 2017 30 sept. 2017 30 juin 2017 31 mars 2017 31 déc. 2016 30 sept. 2016 30 juin 2016 31 mars 2016 31 déc. 2015 30 sept. 2015 30 juin 2015 31 mars 2015
Données financières sélectionnées (US $ en millions)
marge brute 6,677  6,698  6,559  6,436  6,134  6,283  6,401  6,344  6,007  5,459  5,379  5,416  4,922  5,241  4,928  5,047  4,589  4,925  4,777  4,559  4,098 
Revenus nets 8,619  8,704  8,479  8,255  7,828  8,305  8,236  8,278  7,934  7,739  6,995  6,944  6,538  6,796  6,432  6,452  5,958  6,400  5,944  5,475  5,040 
Ratio de rentabilité
Ratio de marge bénéficiaire brute1 77.43% 77.64% 77.32% 77.41% 77.07% 76.44% 75.22% 74.93% 75.18% 75.05% 76.85% 76.78% 76.81% 77.25% 77.21% 78.12% 79.28% 80.31%
Repères
Ratio de marge bénéficiaire brute, concurrents2
Abbott Laboratories 52.13% 52.46% 52.39% 52.17% 51.57% 51.32% 50.57% 50.38% 49.39% 47.75% 48.59% 49.21% 51.32% 54.09% 54.17% 53.99% 53.93% 54.19%
Allergan PLC 83.73% 84.50% 84.96% 85.09% 86.21% 86.12% 86.39% 86.56% 86.03% 86.40% 86.65% 87.11% 87.56% 87.23% 86.55% 81.36% 73.17% 68.08%
Amgen Inc. 78.90% 80.38% 81.19% 81.23% 81.26% 81.80% 81.61% 81.78% 81.69% 81.33% 81.37% 81.26% 81.05% 80.99% 80.68% 80.64% 80.23% 79.82%
Biogen Inc. 87.47% 86.40% 85.97% 85.59% 85.72% 86.50% 86.12% 86.43% 86.57% 86.72% 87.34% 86.80% 86.56% 87.08% 87.46% 88.21% 88.65% 88.48%
Bristol-Myers Squibb Co. 68.08% 69.10% 69.65% 69.93% 70.77% 70.98% 70.37% 70.12% 69.62% 70.80% 71.92% 72.78% 74.19% 74.54% 75.56% 75.55% 75.67% 76.39%
Eli Lilly & Co. 79.22% 78.85% 77.78% 76.67% 74.96% 73.81% 73.39% 72.92% 72.95% 73.46% 73.69% 73.89% 73.78% 73.35% 73.23% 73.72% 74.39% 74.76%
Gilead Sciences Inc. 79.06% 78.86% 79.27% 78.98% 78.02% 77.61% 79.21% 80.31% 81.82% 82.97% 84.51% 84.71% 85.95% 85.77% 86.36% 86.91% 86.69% 87.54%
Illumina Inc. 70.36% 69.63% 69.24% 68.84% 69.06% 69.01% 69.44% 68.85% 67.98% 66.35% 65.68% 66.26% 67.53% 69.48% 69.91% 69.96% 69.74% 69.80%
Johnson & Johnson 66.15% 66.42% 66.49% 66.67% 66.80% 66.79% 66.36% 65.69% 66.22% 66.84% 68.20% 69.35% 69.88% 69.84% 69.52% 69.58% 69.25% 69.27%
Merck & Co. Inc. 70.11% 69.87% 70.13% 69.89% 68.94% 68.06% 67.35% 67.81% 68.22% 68.16% 68.09% 67.92% 66.61% 65.10% 63.89% 62.58% 62.07% 62.19%
Pfizer Inc. 79.94% 80.25% 79.85% 79.91% 79.36% 79.03% 78.58% 78.24% 78.48% 78.61% 78.66% 78.15% 77.28% 76.66% 76.48% 77.71% 79.09% 80.25%
Regeneron Pharmaceuticals Inc. 89.72% 90.05% 91.14% 92.27% 92.79% 93.53% 93.36% 93.28% 92.95% 93.24% 93.37% 94.16% 94.53% 93.83% 92.90% 91.38% 90.52% 90.43%
Vertex Pharmaceuticals Inc. 87.24% 86.84% 86.60% 86.56% 86.74% 86.56% 86.88% 87.31% 87.59% 88.95% 89.04% 89.08% 89.76% 87.64% 87.16% 87.72% 87.39% 87.94%
Zoetis Inc. 69.51% 68.18% 67.38% 66.92% 66.49% 67.19% 68.12% 68.04% 67.31% 66.55% 65.14% 64.91% 65.30% 65.92% 65.32% 64.90% 64.08% 63.53%

La source: AbbVie Inc. (NYSE:ABBV) | Analysis of profitability ratios (Q) (www.stock-analysis-on.net)

1 Q1 2020 calcul
Ratio de marge bénéficiaire brute = 100 × (marge bruteQ1 2020 + marge bruteQ4 2019 + marge bruteQ3 2019 + marge bruteQ2 2019) ÷ (Revenus netsQ1 2020 + Revenus netsQ4 2019 + Revenus netsQ3 2019 + Revenus netsQ2 2019)
= 100 × (6,677 + 6,698 + 6,559 + 6,436) ÷ (8,619 + 8,704 + 8,479 + 8,255) = 77.43%

2 Cliquez sur le nom du concurrent pour voir les calculs.

Ratio de rentabilité La description L’entreprise
Ratio de marge bénéficiaire brute Le ratio de marge bénéficiaire brute indique le pourcentage des revenus disponibles pour couvrir les dépenses d’exploitation et autres. Le ratio de marge bénéficiaire brute d’AbbVie Inc. s’est amélioré du troisième trimestre 2019 au quatrième trimestre 2019, mais s’est ensuite légèrement détérioré du quatrième trimestre 2019 au premier trimestre 2020, n’atteignant pas le niveau du troisième trimestre 2019.

Ratio de marge bénéficiaire d’exploitation

AbbVie Inc., ratio de marge bénéficiaire d’exploitation, calcul (données trimestrielles)

Microsoft Excel LibreOffice Calc
31 mars 2020 31 déc. 2019 30 sept. 2019 30 juin 2019 31 mars 2019 31 déc. 2018 30 sept. 2018 30 juin 2018 31 mars 2018 31 déc. 2017 30 sept. 2017 30 juin 2017 31 mars 2017 31 déc. 2016 30 sept. 2016 30 juin 2016 31 mars 2016 31 déc. 2015 30 sept. 2015 30 juin 2015 31 mars 2015
Données financières sélectionnées (US $ en millions)
Bénéfice d’exploitation 3,603  3,956  2,617  3,400  3,010  (2,441) 3,159  2,762  2,903  1,794  2,705  2,674  2,419  2,358  2,361  2,387  2,278  2,113  1,885  1,852  1,687 
Revenus nets 8,619  8,704  8,479  8,255  7,828  8,305  8,236  8,278  7,934  7,739  6,995  6,944  6,538  6,796  6,432  6,452  5,958  6,400  5,944  5,475  5,040 
Ratio de rentabilité
Ratio de marge bénéficiaire d’exploitation1 39.86% 39.03% 20.04% 21.85% 19.88% 19.49% 32.99% 32.84% 34.03% 33.99% 37.24% 36.74% 36.33% 36.60% 36.21% 35.00% 34.18% 32.97%
Repères
Ratio de marge bénéficiaire d’exploitation, concurrents2
Abbott Laboratories 14.18% 14.21% 13.74% 13.27% 12.31% 11.94% 10.45% 10.11% 8.92% 6.30% 7.89% 8.77% 11.03% 15.27% 14.74% 13.95% 13.64% 14.05%
Allergan PLC -21.34% -27.63% -60.39% -55.48% -50.30% -39.57% -5.95% -32.39% -35.34% -37.15% -43.48% -19.74% -17.36% -12.53% -13.13% -20.47% -15.77% -20.00%
Amgen Inc. 41.89% 43.57% 44.83% 44.05% 44.53% 45.55% 45.82% 46.46% 46.07% 45.76% 46.66% 46.93% 45.68% 44.74% 43.33% 42.46% 41.53% 40.44%
Biogen Inc. 51.03% 48.98% 47.13% 46.90% 42.40% 43.77% 44.67% 45.58% 46.49% 43.54% 40.25% 38.72% 41.59% 44.99% 47.59% 47.86% 47.11% 45.44%
Bristol-Myers Squibb Co. 16.30% 22.62% 28.64% 28.60% 23.44% 22.69% 18.64% 15.93% 17.50% 17.39% 19.71% 21.73% 24.06% 23.83% 19.21% 16.34% 11.09% 11.41%
Eli Lilly & Co. 25.64% 22.29% 20.00% 19.48% 12.50% 15.15% 12.34% 9.11% 14.88% 9.38% 12.43% 14.23% 12.92% 16.30% 14.31% 14.56% 14.27% 13.47%
Gilead Sciences Inc. 19.89% 19.38% 19.71% 38.44% 37.87% 37.83% 42.81% 46.25% 51.51% 55.04% 58.72% 58.71% 58.46% 58.87% 61.67% 63.83% 66.22% 69.03%
Illumina Inc. 27.28% 27.80% 26.42% 24.88% 25.58% 26.49% 28.25% 27.58% 26.29% 22.02% 20.01% 20.06% 21.35% 24.48% 24.80% 24.55% 24.77% 27.61%
Johnson & Johnson 25.62% 24.15% 24.15% 22.63% 22.69% 24.27% 22.59% 23.05% 23.63% 24.07% 27.02% 28.55% 28.83% 28.72% 26.37% 25.66% 25.00% 25.05%
Merck & Co. Inc. 25.49% 24.77% 25.56% 26.73% 24.38% 19.62% 17.84% 12.28% 13.57% 16.28% 9.92% 16.85% 14.45% 13.51% 19.60% 18.10% 18.19% 17.54%
Pfizer Inc. 25.38% 25.46% 26.30% 27.50% 26.86% 26.10% 26.18% 26.00% 25.86% 25.92% 24.69% 23.57% 22.94% 22.73% 22.96% 24.02% 24.86% 24.20%
Regeneron Pharmaceuticals Inc. 30.45% 28.10% 29.55% 29.58% 35.41% 37.77% 37.00% 36.89% 36.54% 35.41% 34.22% 32.29% 28.76% 27.38% 25.67% 26.77% 29.26% 30.51%
Vertex Pharmaceuticals Inc. 34.05% 28.77% 21.38% 25.48% 23.98% 20.84% 22.38% 3.87% -0.77% 4.95% 1.62% 16.16% 14.62% 0.58% -5.02% -8.65% -23.94% -45.23%
Zoetis Inc. 32.72% 31.42% 31.01% 29.80% 30.05% 31.12% 33.00% 33.86% 33.02% 32.15% 29.43% 28.34% 28.55% 28.48% 26.22% 24.91% 17.35% 15.74%

La source: AbbVie Inc. (NYSE:ABBV) | Analysis of profitability ratios (Q) (www.stock-analysis-on.net)

1 Q1 2020 calcul
Ratio de marge bénéficiaire d’exploitation = 100 × (Bénéfice d’exploitationQ1 2020 + Bénéfice d’exploitationQ4 2019 + Bénéfice d’exploitationQ3 2019 + Bénéfice d’exploitationQ2 2019) ÷ (Revenus netsQ1 2020 + Revenus netsQ4 2019 + Revenus netsQ3 2019 + Revenus netsQ2 2019)
= 100 × (3,603 + 3,956 + 2,617 + 3,400) ÷ (8,619 + 8,704 + 8,479 + 8,255) = 39.86%

2 Cliquez sur le nom du concurrent pour voir les calculs.

Ratio de rentabilité La description L’entreprise
Ratio de marge bénéficiaire d’exploitation Un ratio de rentabilité calculé comme le résultat d’exploitation divisé par le chiffre d’affaires. Le ratio de marge bénéficiaire d’exploitation d’AbbVie Inc. s’est amélioré du troisième trimestre 2019 au quatrième trimestre 2019 et du quatrième trimestre 2019 au premier trimestre 2020.

Ratio de marge bénéficiaire nette

AbbVie Inc., ratio de marge bénéficiaire nette, calcul (données trimestrielles)

Microsoft Excel LibreOffice Calc
31 mars 2020 31 déc. 2019 30 sept. 2019 30 juin 2019 31 mars 2019 31 déc. 2018 30 sept. 2018 30 juin 2018 31 mars 2018 31 déc. 2017 30 sept. 2017 30 juin 2017 31 mars 2017 31 déc. 2016 30 sept. 2016 30 juin 2016 31 mars 2016 31 déc. 2015 30 sept. 2015 30 juin 2015 31 mars 2015
Données financières sélectionnées (US $ en millions)
Bénéfice net 3,010  2,801  1,884  741  2,456  (1,826) 2,747  1,983  2,783  52  1,631  1,915  1,711  1,391  1,598  1,610  1,354  1,517  1,239  1,366  1,022 
Revenus nets 8,619  8,704  8,479  8,255  7,828  8,305  8,236  8,278  7,934  7,739  6,995  6,944  6,538  6,796  6,432  6,452  5,958  6,400  5,944  5,475  5,040 
Ratio de rentabilité
Ratio de marge bénéficiaire nette1 24.77% 23.69% 9.90% 12.62% 16.42% 17.36% 23.50% 20.84% 21.55% 18.82% 24.38% 24.77% 24.07% 23.22% 24.08% 23.11% 23.03% 22.50%
Repères
Ratio de marge bénéficiaire nette, concurrents2
Abbott Laboratories 11.15% 11.56% 10.50% 9.36% 8.53% 7.74% 2.91% 3.13% 1.67% 1.74% 8.37% 4.96% 6.74% 6.71% 6.61% 11.08% 12.00% 21.68%
Allergan PLC -15.44% -32.76% -58.50% -54.25% -45.94% -32.28% 14.50% -9.86% -11.51% -25.88% -46.82% 79.17% 82.42% 102.76% 107.27% 31.97% 29.44% 25.98%
Amgen Inc. 33.64% 35.32% 36.14% 35.57% 35.93% 37.25% 9.96% 10.72% 10.11% 9.08% 37.36% 37.24% 36.12% 35.27% 35.19% 34.48% 33.86% 33.13%
Biogen Inc. 40.76% 40.96% 37.91% 37.62% 33.79% 32.93% 24.08% 23.06% 23.54% 20.69% 29.44% 28.10% 30.17% 32.34% 34.03% 33.97% 33.79% 32.95%
Bristol-Myers Squibb Co. 3.08% 13.15% 23.39% 26.00% 22.09% 21.81% 6.50% 1.74% 4.37% 4.85% 20.56% 22.66% 24.22% 22.94% 18.22% 16.29% 9.31% 9.45%
Eli Lilly & Co. 23.97% 37.27% 35.10% 33.76% 26.12% 13.16% 1.85% -0.60% 4.82% -0.89% 9.90% 11.12% 10.13% 12.90% 11.73% 11.97% 11.49% 12.07%
Gilead Sciences Inc. 22.17% 24.35% 12.24% 27.14% 26.93% 25.16% 7.27% 9.69% 14.26% 18.03% 42.90% 43.55% 44.11% 45.07% 48.40% 51.16% 53.48% 56.32%
Illumina Inc. 26.49% 28.28% 28.13% 27.55% 25.05% 24.78% 21.09% 20.88% 19.31% 26.38% 30.14% 30.07% 30.52% 19.29% 18.70% 18.70% 18.40% 20.79%
Johnson & Johnson 20.75% 18.42% 17.32% 20.08% 17.99% 18.75% 1.89% 1.70% 1.58% 1.70% 21.28% 22.52% 22.87% 23.01% 22.27% 21.20% 22.15% 21.99%
Merck & Co. Inc. 21.10% 21.01% 20.26% 21.10% 19.50% 14.71% 8.02% 3.25% 3.88% 5.97% 7.15% 12.71% 10.88% 9.85% 13.76% 13.01% 11.72% 11.25%
Pfizer Inc. 31.17% 31.45% 30.57% 23.58% 21.31% 20.79% 44.63% 42.35% 41.29% 40.55% 18.69% 15.90% 13.88% 13.66% 11.77% 13.47% 14.95% 14.25%
Regeneron Pharmaceuticals Inc. 28.56% 26.91% 28.13% 28.59% 35.12% 36.42% 28.24% 25.65% 23.54% 20.41% 23.17% 22.05% 19.34% 18.42% 16.85% 15.98% 16.72% 15.50%
Vertex Pharmaceuticals Inc. 31.35% 28.27% 59.23% 64.13% 66.01% 68.80% 22.87% 15.84% 9.36% 10.59% 8.53% 12.19% 8.78% -6.58% -13.17% -17.66% -30.91% -53.89%
Zoetis Inc. 25.41% 23.96% 23.76% 22.74% 23.47% 24.52% 20.35% 19.95% 17.97% 16.28% 18.29% 17.50% 17.25% 16.80% 14.10% 13.15% 7.83% 7.11%

La source: AbbVie Inc. (NYSE:ABBV) | Analysis of profitability ratios (Q) (www.stock-analysis-on.net)

1 Q1 2020 calcul
Ratio de marge bénéficiaire nette = 100 × (Bénéfice netQ1 2020 + Bénéfice netQ4 2019 + Bénéfice netQ3 2019 + Bénéfice netQ2 2019) ÷ (Revenus netsQ1 2020 + Revenus netsQ4 2019 + Revenus netsQ3 2019 + Revenus netsQ2 2019)
= 100 × (3,010 + 2,801 + 1,884 + 741) ÷ (8,619 + 8,704 + 8,479 + 8,255) = 24.77%

2 Cliquez sur le nom du concurrent pour voir les calculs.

Ratio de rentabilité La description L’entreprise
Ratio de marge bénéficiaire nette Un indicateur de rentabilité, calculé comme le revenu net divisé par les revenus. Le ratio de marge bénéficiaire nette d’AbbVie Inc. s’est amélioré du troisième trimestre 2019 au quatrième trimestre 2019 et du quatrième trimestre 2019 au premier trimestre 2020.

Rendement des capitaux propres (ROE)

AbbVie Inc., ROE, calcul (données trimestrielles)

Microsoft Excel LibreOffice Calc
31 mars 2020 31 déc. 2019 30 sept. 2019 30 juin 2019 31 mars 2019 31 déc. 2018 30 sept. 2018 30 juin 2018 31 mars 2018 31 déc. 2017 30 sept. 2017 30 juin 2017 31 mars 2017 31 déc. 2016 30 sept. 2016 30 juin 2016 31 mars 2016 31 déc. 2015 30 sept. 2015 30 juin 2015 31 mars 2015
Données financières sélectionnées (US $ en millions)
Bénéfice net 3,010  2,801  1,884  741  2,456  (1,826) 2,747  1,983  2,783  52  1,631  1,915  1,711  1,391  1,598  1,610  1,354  1,517  1,239  1,366  1,022 
Capitaux propres (déficit) (7,415) (8,172) (8,226) (8,566) (7,826) (8,446) (2,921) (3,376) 3,553  5,097  6,687  6,009  4,998  4,636  6,469  5,640  4,643  3,945  4,863  5,504  1,377 
Ratio de rentabilité
ROE1 179.59% 104.16% 99.42% 110.08% 126.25% 128.41% 93.97% 101.42% 117.94% 130.39%
Repères
ROE, concurrents2
Abbott Laboratories 11.84% 11.86% 10.35% 9.14% 8.48% 7.76% 2.89% 3.03% 1.52% 1.54% 6.57% 3.71% 4.79% 6.82% 6.59% 11.02% 11.81% 20.85%
Allergan PLC -4.28% -9.06% -15.82% -14.25% -11.73% -7.83% 3.30% -2.24% -2.55% -5.59% -10.18% 15.86% 16.16% 19.65% 15.99% 5.77% 6.05% 5.11%
Amgen Inc. 80.92% 81.07% 73.83% 73.73% 74.55% 67.15% 15.35% 15.86% 14.21% 7.84% 25.37% 25.77% 25.76% 25.85% 24.65% 24.67% 25.16% 24.71%
Biogen Inc. 46.85% 44.13% 38.55% 40.87% 33.74% 33.98% 23.15% 24.21% 21.09% 20.13% 27.10% 28.42% 30.31% 30.50% 32.06% 33.48% 35.78% 37.84%
Bristol-Myers Squibb Co. 1.91% 6.66% 32.04% 38.65% 33.80% 35.07% 10.50% 3.05% 7.18% 8.58% 28.61% 31.20% 33.55% 27.55% 21.56% 19.24% 10.94% 10.97%
Eli Lilly & Co. 179.72% 319.09% 234.97% 282.08% 252.24% 32.88% 3.44% -1.24% 7.74% -1.76% 14.94% 17.35% 15.58% 19.54% 15.68% 16.85% 15.45% 16.53%
Gilead Sciences Inc. 22.49% 23.91% 13.07% 26.33% 26.84% 25.51% 6.94% 10.19% 16.82% 22.64% 46.69% 53.86% 61.82% 71.48% 89.38% 105.21% 129.43% 97.70%
Illumina Inc. 20.32% 21.72% 21.92% 21.65% 21.36% 21.98% 19.53% 19.90% 18.85% 26.41% 27.38% 27.54% 29.01% 21.06% 19.79% 21.05% 20.82% 24.97%
Johnson & Johnson 28.01% 25.42% 24.31% 26.87% 24.90% 25.60% 2.39% 2.18% 1.97% 2.16% 21.39% 22.71% 23.46% 23.49% 21.91% 20.73% 21.40% 21.66%
Merck & Co. Inc. 38.72% 37.99% 34.70% 33.88% 30.50% 23.30% 10.32% 4.12% 4.69% 6.97% 7.44% 12.89% 10.91% 9.78% 12.55% 11.84% 10.53% 9.94%
Pfizer Inc. 24.28% 25.77% 24.91% 21.24% 19.52% 17.59% 33.40% 32.31% 29.72% 29.88% 16.14% 14.26% 12.49% 12.12% 9.90% 11.22% 12.09% 10.75%
Regeneron Pharmaceuticals Inc. 18.79% 19.08% 20.41% 21.21% 25.70% 27.91% 22.85% 22.14% 21.74% 19.51% 21.12% 20.91% 19.79% 20.13% 17.75% 18.23% 19.69% 17.40%
Vertex Pharmaceuticals Inc. 23.38% 19.34% 40.81% 43.70% 45.63% 47.28% 22.27% 15.46% 9.41% 12.99% 10.93% 15.55% 11.82% -9.69% -21.41% -28.03% -41.73% -59.19%
Zoetis Inc. 58.52% 55.39% 54.56% 57.03% 59.91% 65.35% 54.96% 56.60% 49.90% 48.81% 47.11% 51.20% 53.14% 55.21% 43.47% 47.09% 32.45% 31.74%

La source: AbbVie Inc. (NYSE:ABBV) | Analysis of profitability ratios (Q) (www.stock-analysis-on.net)

1 Q1 2020 calcul
ROE = 100 × (Bénéfice netQ1 2020 + Bénéfice netQ4 2019 + Bénéfice netQ3 2019 + Bénéfice netQ2 2019) ÷ Capitaux propres (déficit)
= 100 × (3,010 + 2,801 + 1,884 + 741) ÷ -7,415 =

2 Cliquez sur le nom du concurrent pour voir les calculs.

Ratio de rentabilité La description L’entreprise
ROE Un ratio de rentabilité calculé en résultat net divisé par les capitaux propres.

Ratio de rendement des actifs (ROA)

AbbVie Inc., ROA, calcul (données trimestrielles)

Microsoft Excel LibreOffice Calc
31 mars 2020 31 déc. 2019 30 sept. 2019 30 juin 2019 31 mars 2019 31 déc. 2018 30 sept. 2018 30 juin 2018 31 mars 2018 31 déc. 2017 30 sept. 2017 30 juin 2017 31 mars 2017 31 déc. 2016 30 sept. 2016 30 juin 2016 31 mars 2016 31 déc. 2015 30 sept. 2015 30 juin 2015 31 mars 2015
Données financières sélectionnées (US $ en millions)
Bénéfice net 3,010  2,801  1,884  741  2,456  (1,826) 2,747  1,983  2,783  52  1,631  1,915  1,711  1,391  1,598  1,610  1,354  1,517  1,239  1,366  1,022 
Total des actifs 91,199  89,115  59,441  57,142  56,769  59,352  66,164  61,641  69,342  70,786  68,840  66,994  65,664  66,099  66,626  67,211  53,720  53,050  54,832  53,855  26,699 
Ratio de rentabilité
ROA1 9.25% 8.84% 5.48% 7.21% 9.44% 9.58% 11.43% 10.46% 9.20% 7.50% 9.66% 9.87% 9.61% 9.01% 9.12% 8.51% 10.19% 9.70%
Repères
ROA, concurrents2
Abbott Laboratories 5.36% 5.43% 4.80% 4.23% 3.88% 3.53% 1.24% 1.35% 0.67% 0.63% 2.91% 1.65% 2.12% 2.66% 3.47% 5.72% 6.17% 10.72%
Allergan PLC -2.81% -5.57% -9.80% -8.91% -7.36% -5.01% 2.18% -1.46% -1.65% -3.49% -6.09% 9.56% 9.58% 11.61% 9.99% 3.34% 3.44% 2.88%
Amgen Inc. 12.45% 13.13% 13.55% 13.40% 12.62% 12.64% 3.27% 3.49% 3.12% 2.48% 10.18% 10.27% 10.14% 9.95% 9.71% 9.85% 9.61% 9.69%
Biogen Inc. 22.51% 21.62% 19.63% 20.14% 17.65% 17.52% 12.50% 12.39% 11.36% 10.73% 15.11% 15.13% 16.42% 16.19% 17.58% 17.75% 17.87% 18.19%
Bristol-Myers Squibb Co. 0.74% 2.65% 9.85% 11.24% 14.77% 14.06% 4.24% 1.15% 2.78% 3.00% 12.45% 13.73% 14.68% 13.22% 9.98% 8.74% 4.94% 4.93%
Eli Lilly & Co. 13.46% 21.17% 20.97% 20.28% 16.46% 7.36% 1.01% -0.34% 2.53% -0.45% 5.17% 5.98% 5.81% 7.05% 6.50% 6.76% 6.68% 6.77%
Gilead Sciences Inc. 8.31% 8.74% 4.55% 9.42% 9.38% 8.57% 2.47% 3.38% 5.30% 6.58% 17.94% 20.27% 21.90% 23.70% 26.63% 32.71% 36.30% 34.93%
Illumina Inc. 12.97% 13.70% 13.73% 13.45% 11.52% 11.87% 10.12% 11.08% 10.23% 13.81% 15.49% 15.39% 16.10% 10.81% 10.49% 10.86% 10.93% 12.52%
Johnson & Johnson 11.07% 9.59% 9.10% 10.53% 9.78% 10.00% 0.99% 0.88% 0.79% 0.83% 10.17% 10.69% 11.39% 11.71% 11.36% 10.75% 11.41% 11.55%
Merck & Co. Inc. 11.95% 11.66% 11.18% 11.15% 10.20% 7.53% 3.93% 1.58% 1.84% 2.72% 3.11% 5.48% 4.50% 4.11% 5.58% 5.32% 4.67% 4.36%
Pfizer Inc. 9.49% 9.72% 9.51% 8.10% 7.38% 7.00% 14.19% 13.67% 13.21% 12.40% 5.70% 4.94% 4.32% 4.20% 3.51% 4.13% 4.68% 4.16%
Regeneron Pharmaceuticals Inc. 14.46% 14.29% 15.38% 15.71% 18.88% 20.83% 16.64% 15.99% 15.23% 13.67% 14.69% 14.24% 12.32% 12.84% 11.68% 11.97% 12.56% 11.34%
Vertex Pharmaceuticals Inc. 16.99% 14.15% 28.53% 31.50% 32.94% 33.57% 14.00% 9.58% 5.72% 7.43% 6.12% 7.91% 6.02% -3.87% -8.38% -10.79% -16.05% -22.26%
Zoetis Inc. 13.97% 12.99% 12.96% 12.52% 12.75% 13.25% 11.13% 12.96% 11.25% 10.06% 10.09% 11.25% 11.18% 10.73% 8.93% 8.50% 5.07% 4.28%

La source: AbbVie Inc. (NYSE:ABBV) | Analysis of profitability ratios (Q) (www.stock-analysis-on.net)

1 Q1 2020 calcul
ROA = 100 × (Bénéfice netQ1 2020 + Bénéfice netQ4 2019 + Bénéfice netQ3 2019 + Bénéfice netQ2 2019) ÷ Total des actifs
= 100 × (3,010 + 2,801 + 1,884 + 741) ÷ 91,199 = 9.25%

2 Cliquez sur le nom du concurrent pour voir les calculs.

Ratio de rentabilité La description L’entreprise
ROA Un ratio de rentabilité calculé comme le bénéfice net divisé par le total de l’actif. Le ROA d’AbbVie Inc. s’est amélioré du troisième trimestre 2019 au quatrième trimestre 2019 et du quatrième trimestre 2019 au premier trimestre 2020.